Ovid therapeutics Inc
Fechado
SetorSaúde
2.35 4.44
Visão Geral
Variação de preço das ações
24h
Mín
2.22
Máximo
2.39
Rendimento | -27M -17M |
|---|---|
EPS | -0.125 |
Margem de lucro | -2,366.017 |
Funcionários | 23 |
EBITDA | -5.5M -18M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +135.84% upside |
Próximos Ganhos | 12 de ago. de 2026 |
|---|
Capitalização de Mercado | -42M 440M |
|---|---|
Abertura anterior | -2.09 |
Fecho anterior | 2.35 |
Sentimento de Notícias
By Acuity
50%
50%
162 / 342 Ranking em Healthcare
Ovid therapeutics Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Ovid therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.